2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $44B | $51B | $62B | $64B | $65B |
Cost of Revenue | $30B | $34B | $42B | $43B | $44B |
Gross Profit | $14B | $16B | $20B | $21B | $21B |
Gross Profit % | 32% | 32% | 32% | 32% | 33% |
R&D Expenses | $871M | $1.1B | $1.1B | $1.3B | $1.2B |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $5.2B | $6B | $7B | $7B | $7.4B |
Dep. & Amort. | $1.8B | $1.9B | $2.1B | $2.3B | $1.4B |
Def. Tax | $171M | $61M | -$213M | -$269M | -$94M |
Stock Comp. | $1.2B | $1.3B | $1.7B | $1.9B | $1.9B |
Chg. in WC | $59M | -$250M | -$1.2B | -$1.7B | -$2.2B |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $8.4B | $8.2B | $7.9B | $9B | $5B |
ST Investments | $94M | $4.3M | $4M | $4.6M | $5.4M |
Cash & ST Inv. | $8.5B | $8.2B | $7.9B | $9B | $5B |
Receivables | $7.8B | $9.7B | $12B | $12B | $14B |
Inventory | $0 | $0 | $0 | $0 | $0 |
Accenture delivered strong Q2 results with 8.5% revenue growth in local currency (5% in USD) to $16.7B, at the top end of guidance, and EPS of $2.82 (2% YoY growth over adjusted EPS).
New bookings were $20.9B (book-to-bill 1.3), including 32 clients with quarterly bookings over $100M; GenAI contributed $1.4B in new bookings and $600M in revenue.
Operating margin for the quarter was 13.5%, down 20 bps YoY (adjusted), primarily due to higher subcontractor costs and ongoing investments; free cash flow was $2.7B, with $2.4B returned to shareholders via buybacks and dividends.
FY25 guidance: revenue growth of 5%-7% in local currency, operating margin expansion of 10-20 bps to 15.6%-15.7%, EPS of $12.55-$12.79 (5%-7% growth), and free cash flow of $8.8B-$9.5B; expects $2B-$3B in acquisitions and to return at least $8.3B to shareholders.
Despite elevated macro and federal sector uncertainty, Accenture sees no broad client pause in new initiatives, continues to win large transformational deals, and reports increasing GenAI adoption; pricing remains stable in a competitive market.